Understanding SGLT2 Inhibitor Immunometabolism and Immune Crosstalk

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have transformed therapy for type 2 diabetes, chronic kidney disease, and heart failure. Clinicians originally attributed these cardiorenal benefits primarily to improved glycemic control, osmotic diuresis, and natriuresis. However, emerging research reveals that these agents exert extensive pleiotropic effects beyond renal glucose reabsorption. Researchers increasingly recognize that SGLT2 inhibitor immunometabolism plays a central role in modulating systemic inflammatory cascades. While early mechanistic studies centered on innate immunity, recent investigations highlight significant actions on adaptive immune pathways. This shift demonstrates that metabolic reprogramming directly reconfigures T-lymphocyte function and fate. Consequently, understanding how these metabolic agents shape adaptive immune responses provides crucial insights into their therapeutic mechanisms. By targeting nutrient-sensing pathways, SGLT2 inhibitors alter cellular energy dynamics, creating an anti-inflammatory microenvironment. Exploring these immunometabolic properties opens novel avenues for therapeutic innovation and cardiorenal risk reduction across diverse patient populations.

Functional SGLT2 Expression in CD4+ T Cells

A key discovery in adaptive immune regulation is the functional expression of SGLT2 on human cluster of differentiation 4 (CD4⁺) T cells. Previously, experts believed SGLT2 expression occurred almost exclusively in proximal renal tubules. However, recent evidence confirms that activated CD4⁺ T lymphocytes express functional SGLT2 proteins, making them directly responsive to pharmacological inhibition. This finding indicates that SGLT2 inhibitors act through both systemic metabolic remodeling and direct cellular mechanisms. Upon activation, T cells increase metabolic demand, requiring rapid glucose uptake and glycolysis for expansion. Pharmacological SGLT2 blockade on T cells alters nutrient sensing and restricts glucose utilization, directly dampening cellular hyperreactivity. Simultaneously, systemic effects—such as mild ketonemia and reduced inflammatory cytokines—reinforce this protective milieu. By demonstrating direct expression on CD4⁺ T cells, researchers have established a firm biological foundation for SGLT2 inhibitor-mediated immunomodulation, linking metabolic intervention directly to adaptive immune control.

Molecular Pathways Driving Immunometabolic Reprogramming

The intracellular signaling network linking SGLT2 inhibition to adaptive immune regulation involves several interconnected nutrient-sensing pathways. Chief among these is the activation of AMP-activated protein kinase (AMPK), a master energy sensor. SGLT2 inhibitors induce a nutrient deprivation state that triggers AMPK phosphorylation, suppressing anabolic processes and stimulating catabolism. Concurrently, AMPK activation downregulates mechanistic target of rapamycin complex 1 (mTORC1) and serum/glucocorticoid-regulated kinase 1 (SGK1) signaling. Because mTORC1 and SGK1 promote pro-inflammatory T-cell differentiation, their inhibition alters cell fate significantly. Additionally, SGLT2 inhibitors stimulate hepatic ketogenesis, raising circulating beta-hydroxybutyrate levels. Ketone bodies serve as alternative energy substrates and signaling molecules that suppress inflammatory pathways. Together, these molecular events induce a fasting-mimetic metabolic state within the microenvironment. This shift decreases glycolytic flux while favoring fatty acid oxidation, effectively converting effector T cells from pro-inflammatory states toward quiescent, regulatory phenotypes.

Restoring Balance in the Th17 and Treg Axis

The T helper 17 (Th17) and regulatory T-cell (Treg) balance serves as a critical axis controlling immune homeostasis and tissue injury. Th17 cells produce pro-inflammatory cytokines like interleukin-17 (IL-17), driving chronic inflammation and organ damage. Conversely, Treg cells express FOXP3 and suppress excessive immune responses to maintain self-tolerance. Imbalance in this axis directly contributes to autoimmune pathogenesis and cardiorenal disease. Immunometabolic reprogramming induced by SGLT2 inhibitors specifically targets this equilibrium. High glycolytic activity and mTORC1 signaling normally favor Th17 differentiation over Treg development. By inhibiting mTORC1 and SGK1 while activating AMPK, SGLT2 inhibitors suppress transcriptional programs driving Th17 commitment. Simultaneously, these signaling changes stabilize FOXP3 expression, promoting Treg generation and suppressive function. Experimental models confirm that SGLT2 inhibition attenuates Th17-mediated inflammatory cytokines and restores a healthy Th17/Treg ratio, providing a robust mechanism for sustained tissue protection.

Preclinical Findings and Clinical Translational Gaps

Preclinical studies provide strong evidence supporting the therapeutic impact of SGLT2 inhibitors on adaptive immunity. In animal models of diabetic nephropathy, heart failure, and systemic inflammation, SGLT2 inhibition consistently attenuates tissue injury, suppresses leukocyte infiltration, and restores Th17/Treg balance. For instance, empagliflozin and dapagliflozin significantly lower systemic IL-17 levels while expanding Treg populations in rodent studies. These findings confirm that targeting immunometabolic pathways yields tangible anti-inflammatory benefits. However, translation into clinical human evidence remains incomplete. Current human trials have primarily evaluated hard clinical outcomes, such as cardiovascular mortality and renal disease progression. Although secondary analyses confirm lower systemic inflammatory markers, detailed clinical evaluations of human T-cell subsets during SGLT2 inhibitor therapy are limited. Experts emphasize that while adaptive immune modulation is biologically plausible, it remains an incompletely validated component of human SGLT2 inhibitor biology requiring further clinical study.

Therapeutic Repurposing in Immune-Mediated Disorders

Modulating adaptive immunity offers exciting prospects for repurposing SGLT2 inhibitors beyond traditional cardiometabolic diseases. Autoimmune conditions like rheumatoid arthritis, lupus nephritis, and inflammatory bowel disease depend on dysregulated Th17 responses and defective Treg function. Because SGLT2 inhibitors favorably balance the Th17/Treg axis through metabolic reprogramming, they represent a promising adjunctive strategy. Combining SGLT2 inhibitors with standard immunosuppressants could enhance anti-inflammatory efficacy while reducing drug dosages and toxicities. Furthermore, patients with overlapping metabolic and autoimmune diseases receive dual cardiorenal and immunomodulatory benefits. However, successful repurposing requires rigorous prospective trials to confirm safety, optimal dosing, and therapeutic efficacy in non-diabetic autoimmune populations. In India and globally, where metabolic and autoimmune disease burdens are significant, repurposing well-tolerated agents could improve outcomes affordably. Ongoing research into SGLT2 inhibitor immunometabolism will clarify its precise role in organ protection and guide expanding clinical applications.

How do SGLT2 inhibitors affect the Th17/Treg axis?

SGLT2 inhibitors alter T-cell metabolic programming by activating AMPK and suppressing mTORC1 and SGK1 pathways. This nutrient-sensing shift inhibits glycolytic flux required for pro-inflammatory Th17 differentiation while stabilizing FOXP3 expression. Consequently, SGLT2 inhibition reduces Th17-mediated inflammatory cytokine production and promotes regulatory T-cell expansion, thereby restoring a balanced Th17/Treg ratio and dampening tissue inflammation across cardiovascular and renal systems.

Are SGLT2 inhibitors currently approved for treating autoimmune diseases?

No, SGLT2 inhibitors are currently approved only for type 2 diabetes, chronic kidney disease, and heart failure. While preclinical evidence demonstrates significant immunomodulatory effects on adaptive T cells, clinical human data in primary autoimmune conditions remain sparse. Current guidelines do not recommend SGLT2 inhibitors as primary immunotherapy. However, ongoing translational research aims to evaluate their potential role as adjunctive therapies in immune-mediated inflammatory disorders.

What mechanisms explain SGLT2 inhibitor effects on immune cells without SGLT2 reabsorption in kidneys?

SGLT2 inhibitors act through both direct cellular and systemic metabolic mechanisms. Directly, activated CD4+ T cells express functional SGLT2 channels, allowing pharmacological blockade to alter cellular nutrient uptake directly. Systemically, SGLT2 inhibitors create a fasting-mimetic metabolic state, enhancing circulating ketone levels like beta-hydroxybutyrate and activating systemic AMPK. These combined actions reprogram lymphocyte metabolism toward oxidative pathways, suppressing inflammatory effector T-cell responses independently of renal glucose excretion.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for specific clinical decision-making. Refer to the latest local and national guidelines for clinical practice.

References

1. Alasbily H et al. Immunometabolic Effects of SGLT2 Inhibitors on the Th17/Treg Axis: Mechanisms, Evidence, and Implications for Therapeutic Repurposing. Mol Biol Rep. 2026 Aug 13. doi: undefined. PMID: 42593596.


2. Deng X et al. Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease. Mol Med. 2021;27(1):43.


3. Packer M. Cardioprotective and renal protective actions of SGLT2 inhibitors: the role of nutrient deprivation signaling and autophagy. Circulation. 2020;142(10):981-989.